Results 161 to 170 of about 8,840 (216)

Frequency of diencephalic syndrome in NMOSD

Acta Neurologica Belgica, 2021
Diencephalic region of the brain harbors sites with a considerable amount of aquaporin-4 expression. Neuromyelitis optica spectrum disorder (NMOSD) primarily involves autoimmune processes against this molecule. However, little is known about the frequency of symptoms of diencephalic involvement in NMOSD patients.To investigate the frequency of symptoms
Masoud Etemadifar, Hosein Nouri, Reza Khorvash, Mehri Salari, Kimia Ghafari, Ali Aghababaee   +5 more
openaire   +2 more sources

Immune reconstitution therapy in NMOSD

Multiple Sclerosis and Related Disorders, 2021
NMO spectrum disorders [NMOSD] is a relapsing autoimmune disorder with attacks of optic neuritis (ON) and transverse myelitis (TM). A large proportion of NMOSD patients have no or a partial recovery after relapse.The neuro-immunological community now has a number of indicated agents for NMOSD therapy including eculizumab [Soliris®], inebilizumab ...
openaire   +2 more sources

NMOSD or GFAP astrocytopathy? A case report

Multiple Sclerosis and Related Disorders, 2020
We describe a 43-year-old female whose manifestations fulfilled the diagnostic criteria of aquaporin-4 IgG negative neuromyelitis optica spectrum disorders (NMOSD). High titer of glial fibrillary acidic protein (GFAP) antibody was detected in cerebrospinal fluid. In this case, some symptoms pertained to NMOSD and some to GFAP antibody-related disorders.
Yue Zhang, Abhijeet Kumar Bhekharee, Xiang Zhang   +2 more
openaire   +2 more sources

NMOSD and MOGAD

Continuum
This article reviews the clinical features, MRI characteristics, diagnosis, and treatment of aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
openaire   +2 more sources

Unveiling Misdiagnosis: Rethinking Seronegative NMOSD

Multiple Sclerosis Journal
Seronegative neuromyelitis optica spectrum disorder (NMOSD) is a diagnostic challenge. This study aimed to characterize misapplication of the 2015 international criteria for seronegative NMOSD. We reviewed 35 consecutive seronegative NMOSD referrals to a tertiary center.
Mary V. Lang, Grant M. Welk, Deena A. Tajfirouz, Kevin D. Chodnicki, Sean J. Pittock, Eoin P. Flanagan, John J. Chen   +6 more
openaire   +2 more sources

Update NMOSD

DNP – Die Neurologie & Psychiatrie, 2023
Katrin Giglhuber, Tania Kümpfel, Achim Berthele   +2 more
openaire   +1 more source

NMOSD leads to unemployment in high educational level people with NMOSD (pwNMOSD): results of an online survey with 146 NMOSD patients.

Proceedings of the BCTRIMS 24th Annual Meeting, 2023
Raquel Vassão Araujo, Bruna Rocha Silveira, Gustavo Elexpe San Martin, Giulia Gamba   +3 more
openaire   +1 more source

Place of anti-IL6R in the therapeutic strategy in NMOSD-AQP4+, MOGAD, and NMOSD double-seronegative patients

Multiple Sclerosis Journal
Background: Anti-interleukin-6 receptor (anti-IL6R) therapy has demonstrated efficacy in AQP4 + NMOSD, and emerging evidence suggests a similar benefit in patients with MOGAD. Objectives: This study aimed to evaluate the role of anti ...
Chloé Comet, Guillaume Jouvenot, Bertrand Bourre, Jonathan Ciron, Bertrand Audoin, Xavier Ayrignac, Mikael Cohen, Romain Deschamps, Françoise Durand-Dubief, Elisabeth Maillart, Caroline Papeix, Hélène Zéphir, Romain Marignier, Aurélie Ruet, Laure Michel, Eric Thouvenot, Nicolas Collongues   +16 more
openaire   +2 more sources